Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

  • End date
    Sep 1, 2035
  • participants needed
  • sponsor
    CARsgen Therapeutics Co., Ltd.
Updated on 4 October 2022
measurable disease
pancreatic adenocarcinoma
pancreatic cancers


A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers


This is an open label, multi-center, Phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in patients with advanced gastric, pancreatic or other specified digestive system cancers.

Following consent, patients must have tumor tissue evaluated by CLDN18.2 IHC assay. Patients meeting all eligibility criteria will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (CT041). Following manufacture of the drug product, subjects will receive preconditioning prior to CT041 infusion. All subjects will be asked to continue to undergo long-term gene safety follow-up.

Condition Gastric Cancer, Pancreatic Cancer
Treatment CT041
Clinical Study IdentifierNCT04404595
SponsorCARsgen Therapeutics Co., Ltd.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Patients are eligible for screening for potential inclusion in the study
Voluntarily signed the ICF
Age ≥ 18 and < 76 years with pathologically/histologically confirmed diagnosis of adenocarcinoma of the stomach or gastroesophageal junction, referred to collectively as STAD, or pancreatic adenocarcinoma (PAAD)
Must have CLDN18.2-positive tumor expression as determined by the CLDN18.2 IHC assay
Failed or been intolerant of prior lines of systemic therapy
Estimated life expectancy > 4 months
At least 1 measurable lesion per RECIST 1.1
ECOG performance status of 0 or 1
Sufficient venous access for leukapheresis collection and no other contraindications to leukapheresis
Patients should have reasonable CBC counts, renal and hepatic functions
Women of childbearing age must undergo a serum pregnancy test with negative results before screening and infusion and be willing to use effective and reliable method of contraception
Men must be willing to use effective and reliable method of contraception for at least 12-months after T-cell infusion
Sufficient nutritional status

Exclusion Criteria

Pregnant or lactating women
HIV, active hepatitis C virus (HCV), or active hepatitis B virus (HBV) infusion
Any uncontrolled active infection
AEs from previous treatment that have not recovered
Patients who have clinically significant thyroid dysfunction
Patients allergic to any drugs of the preconditioning regimen, tocilizumab, dimethyl sulfoxide (DMSO), or CT041 CAR-CLDN18.2 T-cell
Patients who have received prior cellular therapy such as (CAR T, TCR, tumor-infiltrating lymphocytes) or organ transplantation; Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
Patients with heavy tumor burden such as significant lung disease
Untreated CNS, leptomeningeal disease or cord compression
Unstable/active ulcer or digestive tract bleeding or recent digestive surgery that may have increased risk of bleeding
Patients who have a history of esophageal or gastric resection with increased risk of bleeding or perforation
Patients requiring anticoagulant therapy such as warfarin or heparin
Patients requiring long-term antiplatelet therapy
Use of prednisone or other equivalent within 14 days before leukapheresis or preconditioning
Major surgery less than 1 week prior to leukapheresis or 3 weeks prior to preconditioning
Patients have clinical significant cardiac conditions that researchers believe that participating in this clinical trial may endanger the health of the patients
Anticancer treatment within approximately 2 weeks prior to leukapheresis or approximately preconditioning
Patients have clinical significant pulmonary conditions
Patients known to have active autoimmune diseases
Patients with second malignancies in addition to STAD or PAAD
Patients have significant neurologic disorders
Patients are unable or unwilling to comply with the requirements of clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note